4.7 Review

Management of uncommon chemotherapy-induced emergencies

Journal

LANCET ONCOLOGY
Volume 12, Issue 8, Pages 806-814

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(10)70208-4

Keywords

-

Categories

Ask authors/readers for more resources

Chemotherapy can induce various clinical emergencies. Prompt recognition and management of these adverse events are important for avoiding further morbidity and mortality. Some events such as hypersensitivity and extravasation are quite common, whereas emergencies such as neutropenic typhlitis, pancreatitis, and acute haemolysis are very rare. Little information exists on the management of rare chemotherapy-induced emergencies that affect fewer than 1% of patients. We review these uncommon chemotherapy-induced life-threatening emergencies, their pathogenesis and management, and recommendations for rechallenge with the off ending chemotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Radiotherapy in the Management of Paediatric Low-Grade Gliomas

T. Ajithkumar, R. Taylor, R. D. Kortmann

CLINICAL ONCOLOGY (2019)

Editorial Material Oncology

Indeed, Cure is Not Enough - A Reflection on Paediatric Radiation Oncology

T. Ajithkumar, R. D. Kortmann

CLINICAL ONCOLOGY (2019)

Review Oncology

Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE radiotherapy working group

Bianca A. Hoeben, Christian Carrie, Beate Timmermann, Henry C. Mandeville, Lorenza Gandola, Karin Dieckmann, Monica Ramos Albiac, Henriette Magelssen, Yasmin Lassen-Ramshad, Barbora Ondrova, Thankamma Ajithkumar, Claire Alapetite, Brian V. Balgobind, Stephanie Bolle, Alison L. Cameron, Raquel Davila Fajardo, Stefan Dietzsch, Delphine Dumont Lecomte, Marry M. van den Heuvel-Eibrink, Rolf D. Kortmann, Anne Laprie, Patrick Melchior, Laetitia Padovani, Barbara Rombi, Giovanni Scarzello, Rudolf Schwarz, Klaus Seiersen, Enrica Seravalli, Nicola Thorp, Gillian A. Whitfield, Tom Boterberg, Geert O. Janssens

LANCET ONCOLOGY (2019)

Article Oncology

Treating Brain Metastases from Breast Cancer: Outcomes after Stereotactic Radiosurgery

T. G. Wilson, T. Robinson, C. MacFarlane, T. Spencer, C. Herbert, L. Wade, H. Reed, J. P. Braybrooke

CLINICAL ONCOLOGY (2020)

Review Oncology

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jan Hudecek, Leonie Voorwerk, Maartje van Seijen, Iris Nederlof, Michiel de Maaker, Jose van den Berg, Koen K. van de Vijver, Karolina Sikorska, Sylvia Adams, Sandra Demaria, Giuseppe Viale, Torsten O. Nielsen, Sunil S. Badve, Stefan Michiels, William Fraser Symmans, Christos Sotiriou, David L. Rimm, Stephen M. Hewitt, Carsten Denkert, Sibylle Loibl, Sherene Loi, John M. S. Bartlett, Giancarlo Pruneri, Deborah A. Dillon, Maggie C. U. Cheang, Andrew Tutt, Jacqueline A. Hall, Zuzana Kos, Roberto Salgado, Marleen Kok, Hugo M. Horlings

NPJ BREAST CANCER (2020)

Review Oncology

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Mohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, Jeppe Thagaard, Weijie Chen, Sarah Dudgeon, Ashish Sharma, Jennifer K. Kerner, Carsten Denkert, Yinyin Yuan, Khalid AbdulJabbar, Stephan Wienert, Peter Savas, Leonie Voorwerk, Andrew H. Beck, Anant Madabhushi, Johan Hartman, Manu M. Sebastian, Hugo M. Horlings, Jan Hudecek, Francesco Ciompi, David A. Moore, Rajendra Singh, Elvire Roblin, Marcelo Luiz Balancin, Marie-Christine Mathieu, Jochen K. Lennerz, Pawan Kirtani, I-Chun Chen, Jeremy P. Braybrooke, Giancarlo Pruneri, Sandra Demaria, Sylvia Adams, Stuart J. Schnitt, Sunil R. Lakhani, Federico Rojo, Laura Comerma, Sunil S. Badve, Mehrnoush Khojasteh, W. Fraser Symmans, Christos Sotiriou, Paula Gonzalez-Ericsson, Katherine L. Pogue-Geile, Rim S. Kim, David L. Rimm, Giuseppe Viale, Stephen M. Hewitt, John M. S. Bartlett, Frederique Penault-Llorca, Shom Goel, Huang-Chun Lien, Sibylle Loibl, Zuzana Kos, Sherene Loi, Matthew G. Hanna, Stefan Michiels, Marleen Kok, Torsten O. Nielsen, Alexander J. Lazar, Zsuzsanna Bago-Horvath, Loes F. S. Kooreman, Jeroen A. W. M. van der Laak, Joel Saltz, Brandon D. Gallas, Uday Kurkure, Michael Barnes, Roberto Salgado, Lee A. D. Cooper

NPJ BREAST CANCER (2020)

Article Oncology

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Zuzana Kos, Elvire Roblin, Rim S. Kim, Stefan Michiels, Brandon D. Gallas, Weijie Chen, Koen K. van de Vijver, Shom Goel, Sylvia Adams, Sandra Demaria, Giuseppe Viale, Torsten O. Nielsen, Sunil S. Badve, W. Fraser Symmans, Christos Sotiriou, David L. Rimm, Stephen Hewitt, Carsten Denkert, Sibylle Loibl, Stephen J. Luen, John M. S. Bartlett, Peter Savas, Giancarlo Pruneri, Deborah A. Dillon, Maggie Chon U. Cheang, Andrew Tutt, Jacqueline A. Hall, Marleen Kok, Hugo M. Horlings, Anant Madabhushi, Jeroen van der Laak, Francesco Ciompi, Anne-Vibeke Laenkholm, Enrique Bellolio, Tina Gruosso, Stephen B. Fox, Juan Carlos Araya, Giuseppe Floris, Jan Hudecek, Leonie Voorwerk, Andrew H. Beck, Jen Kerner, Denis Larsimont, Sabine Declercq, Gert Van den Eynden, Lajos Pusztai, Anna Ehinger, Wentao Yang, Khalid AbdulJabbar, Yinyin Yuan, Rajendra Singh, Crispin Hiley, Maise al Bakir, Alexander J. Lazar, Stephen Naber, Stephan Wienert, Miluska Castillo, Giuseppe Curigliano, Maria-Vittoria Dieci, Fabrice Andre, Charles Swanton, Jorge Reis-Filho, Joseph Sparano, Eva Balslev, I-Chun Chen, Elisabeth Ida Specht Stovgaard, Katherine Pogue-Geile, Kim R. M. Blenman, Frederique Penault-Llorca, Stuart Schnitt, Sunil R. Lakhani, Anne Vincent-Salomon, Federico Rojo, Jeremy P. Braybrooke, Matthew G. Hanna, M. Teresa Soler-Monso, Daniel Bethmann, Carlos A. Castaneda, Karen Willard-Gallo, Ashish Sharma, Huang-Chun Lien, Susan Fineberg, Jeppe Thagaard, Laura Comerma, Paula Gonzalez-Ericsson, Edi Brogi, Sherene Loi, Joel Saltz, Frederick Klaushen, Lee Cooper, Mohamed Amgad, David A. Moore, Roberto Salgado

NPJ BREAST CANCER (2020)

Article Medicine, General & Internal

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Andrew N. J. Tutt, Judy E. Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmana, Susan M. Domchek, Karen A. Gelmon, Simon J. Hollingsworth, Larissa A. Korde, Barbro Linderholm, Hanna Bandos, E. Senkus, Jennifer M. Suga, Z. Shao, Andrew W. Pippas, Zbigniew Nowecki, Tomasz Huzarski, Patricia A. Ganz, Peter C. Lucas, Nigel Baker, Sibylle Loibl, Robin McConnell, Martine Piccart, Rita Schmutzler, Guenther G. Steger, Joseph P. Costantino, Amal Arahmani, Norman Wolmark, Eleanor McFadden, Vassiliki Karantza, Sunil R. Lakhani, Greg Yothers, Christine Campbell, Charles E. Geyer

Summary: In patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than placebo. Olaparib had limited effects on global patient-reported quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Oncology

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

R. Bradley, J. Braybrooke, R. Gray, R. K. Hills, Z. Liu, H. Pan, R. Peto, D. Dodwell, P. McGale, C. Taylor, J. Bergh, S. Swain, P. A. Francis, M. Gnant, F. Perrone, M. M. Regan

Summary: Aromatase inhibitors are more effective than tamoxifen in reducing the risk of breast cancer recurrence in premenopausal women receiving ovarian suppression. The main benefit is observed in the first 4 years of treatment, with no additional benefit or loss of benefit in the following years up to 10.

LANCET ONCOLOGY (2022)

Review Oncology

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Khalid El Bairi, Harry R. Haynes, Elizabeth Blackley, Susan Fineberg, Jeffrey Shear, Sophia Turner, Juliana Ribeiro de Freitas, Daniel Sur, Luis Claudio Amendola, Masoumeh Gharib, Amine Kallala, Indu Arun, Farid Azmoudeh-Ardalan, Luciana Fujimoto, Luz F. Sua, Shi-Wei Liu, Huang-Chun Lien, Pawan Kirtani, Marcelo Balancin, Hicham El Attar, Prerna Guleria, Wenxian Yang, Emad Shash, I-Chun Chen, Veronica Bautista, Jose Fernando Do Prado Moura, Bernardo L. Rapoport, Carlos Castaneda, Eunice Spengler, Gabriela Acosta-Haab, Isabel Frahm, Joselyn Sanchez, Miluska Castillo, Najat Bouchmaa, Reena R. Md Zin, Ruohong Shui, Timothy Onyuma, Wentao Yang, Zaheed Husain, Karen Willard-Gallo, An Coosemans, Edith A. Perez, Elena Provenzano, Paula Gonzalez Ericsson, Eduardo Richardet, Ravi Mehrotra, Sandra Sarancone, Anna Ehinger, David L. Rimm, John M. S. Bartlett, Giuseppe Viale, Carsten Denkert, Akira I. Hida, Christos Sotiriou, Sibylle Loibl, Stephen M. Hewitt, Sunil Badve, William Fraser Symmans, Rim S. Kim, Giancarlo Pruneri, Shom Goel, Prudence A. Francis, Gloria Inurrigarro, Rin Yamaguchi, Hernan Garcia-Rivello, Hugo Horlings, Said Afqir, Roberto Salgado, Sylvia Adams, Marleen Kok, Maria Vittoria Dieci, Stefan Michiels, Sandra Demaria, Sherene Loi

Summary: The use of immune-checkpoint inhibitors has significantly improved survival in cancer patients, including a subgroup of women with breast cancer who may benefit from this treatment. Studies have shown that tumor-infiltrating lymphocytes are associated with response to both cytotoxic treatments and immunotherapy, particularly in patients with triple-negative breast cancer.

NPJ BREAST CANCER (2021)

Article Oncology

Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy

P. J. Ross, H. S. Wasan, D. Croagh, M. Nikfarjam, N. Nguyen, M. Aghmesheh, A. M. Nagrial, D. Bartholomeusz, A. Hendlisz, T. Ajithkumar, C. Iwuji, N. E. Wilson, D. M. Turner, D. C. James, E. Young, M. T. Harris

Summary: This study suggests that combining P-32 microparticles with standard-of-care chemotherapy may have clinically relevant benefits for patients with unresectable locally advanced pancreatic cancer. The treatment has an acceptable safety profile and results in improved local disease control and overall survival.

ESMO OPEN (2022)

Article Oncology

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)

Johnathan K. Joffe, Fay H. Cafferty, Laura Murphy, Gordon J. S. Rustin, Syed A. Sohaib, Rhian Gabe, Sally P. Stenning, Elizabeth James, Dipa Noor, Simona Wade, Francesca Schiavone, Sarah Swift, Elaine Dunwoodie, Marcia Hall, Anand Sharma, Jeremy Braybrooke, Jonathan Shamash, John Logue, Henry H. Taylor, Ivo Hennig, Jeff White, Sarah Rudman, Jane Worlding, David Bloomfield, Guy Faust, Hilary Glen, Rachel Jones, Michael Seckl, Graham MacDonald, Thiagarajan Sreenivasan, Satish Kumar, Andrew Protheroe, Ramachandran Venkitaraman, Danish Mazhar, Victoria Coyle, Martin Highley, Tom Geldart, Robert Laing, Richard S. Kaplan, Robert A. Huddart

Summary: The purpose of this study was to evaluate whether MRI or a reduced scan schedule could be used without increasing early relapse. The results showed that MRI can be recommended to reduce irradiation and a reduced scan schedule does not have adverse effects on long-term outcomes.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

J. Bergh, K. Pritchard, S. Swain, D. Cameron, K. Albain, S. Anderson, R. Arriagada, J. Bartlett, E. Bergsten-Nordstrom, J. Bliss, R. Bradley, E. Brain, J. Braybrooke, L. Carey, M. Clarke, R. Coleman, J. Cuzick, N. Davidson, L. Del Mastro, A. Di Leo, J. Dignam, D. Dodwell, M. Dowsett, F. Duane, B. Ejlertsen, P. Francis, R. Gelber, M. Gnant, M. Goetz, P. Goodwin, R. Gray, P. Halpin-Murphy, D. Hayes, C. Hill, R. Jagsi, W. Janni, Z. Liu, S. Loibl, E. MacKinnon, E. Mamounas, G. Mannu, M. Martin, P. McGale, H. Mukai, V Nekljudova, L. Norton, Y. Ohashi, H. Pan, R. Peto, M. Piccart, L. Pierce, P. Poortmans, V Raina, D. Rea, M. Regan, J. Robertson, E. Rutgers, D. Slamon, T. Spanic, J. Sparano, G. Steger, C. Taylor, G. Tang, M. Toi, A. Tutt, G. Viale, X. Wang, T. Whelan, N. Wilcken, N. Wolmark

Summary: The study demonstrates that adding trastuzumab to chemotherapy for early-stage, HER2-positive breast cancer significantly reduces the risk of breast cancer recurrence and death, with worthwhile proportional reductions irrespective of recorded patient and tumor characteristics.

LANCET ONCOLOGY (2021)

Article Oncology

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

Nicholas C. Turner, Belinda Kingston, Lucy S. Kilburn, Sarah Kernaghan, Andrew M. Wardley, Iain R. Macpherson, Richard D. Baird, Rebecca Roylance, Peter Stephens, Olga Oikonomidou, Jeremy P. Braybrooke, Mark Tuthill, Jacinto Abraham, Matthew C. Winter, Hannah Bye, Michael Hubank, Heidrun Gevensleben, Ros Cutts, Claire Snowdon, Daniel Rea, David Cameron, Abeer Shaaban, Katrina Randle, Sue Martin, Katie Wilkinson, Laura Moretti, Judith M. Bliss, Alistair Ring

LANCET ONCOLOGY (2020)

No Data Available